Groupe Hospitalier Bretagne Sud
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at Groupe Hospitalier Bretagne Sud is advancing treatments for Atopic Dermatitis, focusing on innovative oral and injectable agents that aim to reduce inflammation and improve skin barrier function.
- Evaluation of a JAK inhibitor for moderate to severe disease
- Assessment of IL‑23 targeting antibody combined with standard topical therapy
- Exploration of patient‑reported outcome measures to gauge symptom relief
These studies prioritize safety and quality‑of‑life endpoints, offering new options for individuals who have not responded to conventional therapies.
Neoplasms
Clinical investigations at the Lorient hospital address challenging cancers such as Adenocarcinoma of the prostate and head‑and‑neck squamous cell carcinoma, testing novel drug combinations designed to extend progression‑free survival.
- Combination of radiotherapy with a DNA‑repair inhibitor and cetuximab
- Comparison of androgen deprivation therapy with and without darolutamide in metastatic prostate cancer
- Use of imaging biomarkers to monitor treatment response
The trials aim to improve therapeutic effectiveness for patients who are not candidates for more aggressive chemotherapy.
Pathological Conditions, Signs and Symptoms
Research at the site also concentrates on measurable disease activity in skin disorders, employing validated scoring systems to track improvement.
- Application of the Eczema Area and Severity Index to quantify lesion reduction
- Use of the Validated Investigator’s Global Assessment for atopic dermatitis severity
- Long‑term safety monitoring of combination topical and systemic therapies
By focusing on objective symptom metrics, these studies support better management strategies for patients experiencing chronic dermatologic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 73 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Bretagne Sud
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 10 | Unknown | 2015-06-26 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.